ARS Pharmaceuticals (SPRY) Competitors $14.99 +0.52 (+3.59%) Closing price 04:00 PM EasternExtended Trading$14.74 -0.25 (-1.67%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRY vs. SRPT, BPMC, TLX, AXSM, KRYS, NUVL, GRFS, ELAN, VRNA, and ADMAShould you be buying ARS Pharmaceuticals stock or one of its competitors? The main competitors of ARS Pharmaceuticals include Sarepta Therapeutics (SRPT), Blueprint Medicines (BPMC), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Axsome Therapeutics (AXSM), Krystal Biotech (KRYS), Nuvalent (NUVL), Grifols (GRFS), Elanco Animal Health (ELAN), Verona Pharma (VRNA), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. ARS Pharmaceuticals vs. Sarepta Therapeutics Blueprint Medicines Telix Pharmaceuticals Limited American Depositary Shares Axsome Therapeutics Krystal Biotech Nuvalent Grifols Elanco Animal Health Verona Pharma ADMA Biologics ARS Pharmaceuticals (NASDAQ:SPRY) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, community ranking, analyst recommendations, earnings and media sentiment. Do analysts prefer SPRY or SRPT? ARS Pharmaceuticals currently has a consensus target price of $31.00, indicating a potential upside of 112.18%. Sarepta Therapeutics has a consensus target price of $161.83, indicating a potential upside of 201.13%. Given Sarepta Therapeutics' higher possible upside, analysts plainly believe Sarepta Therapeutics is more favorable than ARS Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ARS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Sarepta Therapeutics 0 Sell rating(s) 5 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 2.83 Do institutionals & insiders have more ownership in SPRY or SRPT? 68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 40.1% of ARS Pharmaceuticals shares are held by company insiders. Comparatively, 7.7% of Sarepta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is SPRY or SRPT more profitable? Sarepta Therapeutics has a net margin of 7.43% compared to ARS Pharmaceuticals' net margin of 0.00%. Sarepta Therapeutics' return on equity of 11.00% beat ARS Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ARS PharmaceuticalsN/A -22.56% -21.82% Sarepta Therapeutics 7.43%11.00%3.35% Does the MarketBeat Community favor SPRY or SRPT? Sarepta Therapeutics received 1446 more outperform votes than ARS Pharmaceuticals when rated by MarketBeat users. However, 86.21% of users gave ARS Pharmaceuticals an outperform vote while only 75.05% of users gave Sarepta Therapeutics an outperform vote. CompanyUnderperformOutperformARS PharmaceuticalsOutperform Votes2586.21% Underperform Votes413.79%Sarepta TherapeuticsOutperform Votes147175.05% Underperform Votes48924.95% Which has more risk & volatility, SPRY or SRPT? ARS Pharmaceuticals has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Does the media favor SPRY or SRPT? In the previous week, Sarepta Therapeutics had 29 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 38 mentions for Sarepta Therapeutics and 9 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 1.23 beat Sarepta Therapeutics' score of 0.26 indicating that ARS Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sarepta Therapeutics 9 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 4 Negative mention(s) 4 Very Negative mention(s) Neutral Which has better earnings and valuation, SPRY or SRPT? ARS Pharmaceuticals has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioARS Pharmaceuticals$89.15M16.08-$54.37M$0.08182.63Sarepta Therapeutics$1.90B2.74-$535.98M$2.2823.57 SummarySarepta Therapeutics beats ARS Pharmaceuticals on 12 of the 18 factors compared between the two stocks. Remove Ads Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRY vs. The Competition Export to ExcelMetricARS PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.43B$6.31B$5.32B$7.60BDividend YieldN/A3.23%5.11%4.33%P/E Ratio-28.656.8021.7517.84Price / Sales16.08223.34378.5093.37Price / CashN/A65.6738.1534.64Price / Book6.095.836.444.01Net Income-$54.37M$141.86M$3.20B$247.23M7 Day Performance18.49%9.23%6.58%7.44%1 Month Performance23.08%-12.42%-8.54%-6.13%1 Year Performance58.12%-12.15%10.13%-0.02% ARS Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRYARS Pharmaceuticals3.2812 of 5 stars$14.99+3.6%$31.00+106.8%+60.4%$1.42B$89.15M-29.3990Gap DownSRPTSarepta Therapeutics4.6725 of 5 stars$52.76-3.1%$163.18+209.3%-55.5%$5.10B$1.90B42.05840Short Interest ↑BPMCBlueprint Medicines2.6248 of 5 stars$79.35-2.9%$124.95+57.5%-5.4%$5.09B$508.82M-73.76640Positive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$14.36+5.5%$22.00+53.2%N/A$4.85B$783.21M0.00N/AAXSMAxsome Therapeutics4.5823 of 5 stars$97.90-1.0%$169.80+73.4%+49.7%$4.79B$385.69M-16.40380Analyst RevisionKRYSKrystal Biotech4.6447 of 5 stars$164.39-4.0%$220.00+33.8%-2.7%$4.76B$290.52M55.25210NUVLNuvalent1.9873 of 5 stars$64.60-1.7%$113.44+75.6%+6.9%$4.62BN/A-18.6240Positive NewsGRFSGrifols3.0949 of 5 stars$6.58-1.1%N/A+6.7%$4.53B$7.21B5.6326,300Gap DownELANElanco Animal Health4.3408 of 5 stars$8.97-2.0%$15.17+69.2%-39.4%$4.46B$4.44B22.459,800Analyst ForecastNews CoverageGap DownVRNAVerona Pharma2.2607 of 5 stars$54.68+1.4%$69.14+26.5%+263.4%$4.41B$42.28M-28.4330Positive NewsGap DownADMAADMA Biologics1.8854 of 5 stars$18.33+1.7%$22.50+22.8%+247.3%$4.35B$426.45M65.69530Options VolumeNews CoveragePositive NewsGap Up Remove Ads Related Companies and Tools Related Companies SRPT Competitors BPMC Competitors TLX Competitors AXSM Competitors KRYS Competitors NUVL Competitors GRFS Competitors ELAN Competitors VRNA Competitors ADMA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRY) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SPRY Stock Free SPRY Stock Alerts